Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cattle material in OTCs

This article was originally published in The Tan Sheet

Executive Summary

An FDA proposed rule would prohibit the use of certain cattle materials in drugs and homeopathics to prevent the spread of bovine spongiform encephalopathy, according to a Federal Register notice published Jan. 12. The list of materials prohibited from use includes items such as the brain, skull, eyes and spinal cord from cattle 30 months and older. The notice points out homeopathic preparations and OTCs approved through the monograph process will be required to comply with the rule, even though they have not been approved through a new drug application. "Although FDA's database of these products is incomplete, some of them may contain cattle materials that would be prohibited under this proposed rule. The requirements proposed...apply to all drugs for humans, including those marketed without an approved application," the notice states. Comments on the proposed rule are due by March 13...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS100106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel